Imbruvica Boosts CLL Lead With First-Line Claim
This article was originally published in Scrip
Executive Summary
AbbVie Inc. and Johnson & Johnson's BTK inhibitor Imbruvica (ibrutinib) has reinforced its lead position in the chronic lymphocytic leukemia market with a first-line indication from FDA.
You may also be interested in...
Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says
Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.
Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says
Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.
J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches
Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.